Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called transcranial direct current stimulation (tDCS) that can be done at home. Over four weeks, researchers want to see if this treatment can help improve symptoms of Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD), as well as help with cognitive control, which is how well someone can manage their thoughts and actions. They are also interested in finding out if the effects of tDCS depend on how much treatment a person receives.
To participate in this study, you need to be between 18 and 65 years old and have a diagnosis of ADD or ADHD. However, there are some conditions that would prevent someone from joining, such as having epilepsy, certain medical implants, or severe mental health issues. If you decide to join, you can expect to receive tDCS treatment at home and help researchers learn more about how this method might benefit people with ADHD. This trial is currently recruiting participants, so it could be an opportunity to explore a new treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and female outpatients 18-65 years of age
- • 2. A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
- Exclusion Criteria:
- • 1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
- • 2. Active substance dependence (except for tobacco).
- • 3. Pregnant or nursing females.
- • 4. Inability to participate in testing procedures.
- • 5. Premorbid neurological conditions (including neurovascular and neurodegenerative diseases such as traumatic brain injury, stroke, Parkinson's, AD and other dementias) and severe psychiatric disorders (bipolar disorder, schizophrenia).
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlestown, Massachusetts, United States
Patients applied
Trial Officials
Joan Camprodon, MD, PHD, MPH
Principal Investigator
MGB: Division of Neuropsychiatry and Neuromodulation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials